Open-Label Treatment Trial to Assess the Short-Term Tolerability, Safety, and Efficacy of Methylphenidate Hydrochloride Extended-Release Liquid Formulation in High-Functioning Autism Spectrum Disorder Adults With Attention-Deficit/Hyperactivity Disorder

Trial Profile

Open-Label Treatment Trial to Assess the Short-Term Tolerability, Safety, and Efficacy of Methylphenidate Hydrochloride Extended-Release Liquid Formulation in High-Functioning Autism Spectrum Disorder Adults With Attention-Deficit/Hyperactivity Disorder

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 01 Feb 2017

At a glance

  • Drugs Methylphenidate (Primary)
  • Indications Attention-deficit hyperactivity disorder; Autistic disorder
  • Focus Therapeutic Use
  • Most Recent Events

    • 22 Dec 2016 Planned End Date changed from 1 Nov 2016 to 1 Nov 2017.
    • 22 Dec 2016 Planned primary completion date changed from 1 Nov 2016 to 1 Nov 2017.
    • 22 Sep 2015 Planned End Date changed from 1 Nov 2015 to 1 Nov 2016, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top